A shortage listing ends. 21 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Shortage listings
Page 6 of 13 of this archive, newest first.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
The 29-day notice: how a compounding wind-down works in South Korea
The document is four pages. Three of them are about dates.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 14 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 4 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Two-thirds back: the extension nobody expected to be the headline
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
The 7-day notice: how a compounding wind-down works in Australia
The document is four pages. Three of them are about dates.
The 27-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
The 11-day notice: how a compounding wind-down works in Italy
The document is four pages. Three of them are about dates.
The 16-day notice: how a compounding wind-down works in the United Arab Emirates
The document is four pages. Three of them are about dates.
A shortage listing ends. 22 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 21-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
The lead-in, the randomisation, and the year that followed
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
The shortage years, and what they taught about interruption
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
The 10-day notice: how a compounding wind-down works in Argentina
The document is four pages. Three of them are about dates.
The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.